Age dependency of cerebral P-gp function measured with (R)-[ 11C]verapamil and PET

European Journal of Clinical Pharmacology

Volumn 65, Issue 9, 2009, Pages 941-946

  Bauer, Martin ^a   Karch, Rudolf ^a   Neumann, Friederike ^a   Abrahim, Aiman ^a   Wagner, Claudia C ^a   Kletter, Kurt ^a   Müller, Markus ^a   Zeitlinger, Markus ^a   Langer, Oliver ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

Author keywords

(R) 11C verapamil; Age; Blood brain barrier; P glycoprotein; Positron emission tomography

Indexed keywords

CARBON 11; GLYCOPROTEIN P; TRACER; UNCLASSIFIED DRUG; VERAPAMIL; VERAPAMIL C 11;

ADULT; AGE; AGED; AMYGDALOID NUCLEUS; AREA UNDER THE CURVE; ARTERIAL BLOOD; ARTICLE; BLOOD BRAIN BARRIER; CEREBELLUM; CORRELATION ANALYSIS; DISTRIBUTION VOLUME; DRUG METABOLISM; FEMALE; FRONTAL LOBE; HUMAN; HUMAN EXPERIMENT; INSULA; ISOTOPE LABELING; MALE; NORMAL HUMAN; PARAMETER; PARTIAL VOLUME CORRECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; STATISTICAL PARAMETRIC MAPPING; TECHNIQUE; TEMPORAL LOBE;

ADULT; AGE FACTORS; AGED; AGING; AMYGDALA; BLOOD-BRAIN BARRIER; BRAIN; CARBON RADIOISOTOPES; CEREBELLUM; CEREBRAL CORTEX; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; VASODILATOR AGENTS; VERAPAMIL;

EID: 69249215171     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0709-5     Document Type: Article

References (18)

1. W Löscher H Potschka 2005 Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases Prog Neurobiol 76 22 76 (Pubitemid 41033402)
2. M Lubberink G Luurtsema BN van Berckel R Boellaard R Toornvliet AD Windhorst EJ Franssen AA Lammertsma 2007 Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[(11)C]verapamil and PET J Cereb Blood Flow Metab 27 424 433
3. JP Bankstahl C Kuntner A Abrahim R Karch J Stanek T Wanek W Wadsak K Kletter M Müller W Löscher O Langer 2008 Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET J Nucl Med 49 1328 1335
4. AL Bartels R Kortekaas J Bart AT Willemsen OL de Klerk JJ de Vries JC van Oostrom KL Leenders 2008 Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration Neurobiol Aging 10.1016/j.neurobiolaging.2008.02.002
5. R Toornvliet BN van Berckel G Luurtsema M Lubberink AA Geldof TM Bosch R Oerlemans AA Lammertsma EJ Franssen 2006 Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography Clin Pharmacol Ther 79 540 548
6. BN van Berckel M Lubberink G Luurtsema R Boellaard AA Lammertsma 2008 Regional variations in age dependence of P-gp mediated transport across the blood-brain barrier measured using (R)-[11C]verapamil and positron emission tomography [symposium abstract] Alzheimers Dement 4 T95
7. AL Bartels AT Willemsen R Kortekaas BM de Jong R de Vries O de Klerk JC van Oostrom A Portman KL Leenders 2008 Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA J Neural Transm 115 1001 1009
8. O Langer M Bauer A Hammers R Karch E Pataraia MJ Koepp A Abrahim G Luurtsema M Brunner R Sunder-Plassmann F Zimprich C Joukhadar S Gentzsch R Dudczak K Kletter M Müller C Baumgartner 2007 Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[11C]verapamil Epilepsia 48 1774 1784
9. OL de Klerk AT Willemsen M Roosink AL Bartels N Harry Hendrikse FJ Bosker JA den Boer 2009 Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier Int J Neuropsychopharmacol 10.1017/S1461145709009894
10. A Hammers R Allom MJ Koepp SL Free R Myers L Lemieux TN Mitchell DJ Brooks JS Duncan 2003 Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe Hum Brain Mapp 19 224 247
11. M Brunner O Langer R Sunder-Plassmann G Dobrozemsky U Müller W Wadsak A Krcal R Karch C Mannhalter R Dudczak K Kletter I Steiner C Baumgartner M Müller 2005 Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans Clin Pharmacol Ther 78 182 190
12. A Abrahim G Luurtsema M Bauer R Karch M Lubberink E Pataraia C Joukhadar K Kletter AA Lammertsma C Baumgartner M Müller O Langer 2008 Peripheral metabolism of (R)-[(11)C]verapamil in epilepsy patients Eur J Nucl Med Mol Imaging 35 116 123
13. R Hurlemann TE Schlaepfer A Matusch H Reich NJ Shah K Zilles W Maier A Bauer 2009 Reduced 5-HT2A receptor signaling following selective bilateral amygdala damage Soc Cogn Affect Neurosci 10.1093/scan/nsn039
14. AG Mukhin AS Kimes SI Chefer JA Matochik CS Contoreggi AG Horti DB Vaupel O Pavlova EA Stein 2008 Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380 J Nucl Med 49 1628 1635
15. M Eichelbaum G Mikus B Vogelgesang 1984 Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration Br J Clin Pharmacol 17 453 458
16. C Dagenais J Zong J Ducharme GM Pollack 2001 Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds Pharm Res 18 957 963
17. JS Liow W Kreisl SS Zoghbi N Lazarova N Seneca RL Gladding A Taku P Herscovitch VW Pike RB Innis 2009 P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys J Nucl Med 50 108 115
18. S Syvänen R Xie S Sahin M Hammarlund-Udenaes 2006 Pharmacokinetic consequences of active drug efflux at the blood-brain barrier Pharm Res 23 705 717